Johnson & Johnson (NYSE:JNJ) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,854,068 shares of the company’s stock after selling 118,455 shares during the quarter. Ensign Peak Advisors Inc owned 0.08% of Johnson & Johnson worth $270,991,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $27,000. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the 1st quarter worth about $31,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $44,000. MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $43,000. Finally, Grayhawk Investment Strategies Inc. boosted its stake in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after buying an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $164.11 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock’s 50 day simple moving average is $161.30 and its 200-day simple moving average is $154.20. The company has a market cap of $394.96 billion, a PE ratio of 10.23, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the firm posted $2.80 EPS. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Friday. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.